Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma.
de Jong A, Kwee TC, de Klerk JM, Adam JA, de Keizer B, Fijnheer R, Kersten MJ, Ludwig I, Jauw YW, Zijlstra JM, Pieters-Van den Bos IC, Stoker J, Hoekstra OS, Nievelstein RA. de Jong A, et al. Among authors: kersten mj. Am J Nucl Med Mol Imaging. 2014 Apr 25;4(3):231-8. eCollection 2014. Am J Nucl Med Mol Imaging. 2014. PMID: 24795837 Free PMC article.
Computed Tomography Observer Agreement in Staging Malignant Lymphoma.
de Jong A, Kwee TC, Quarles van Ufford HM, Beek FJ, Quekel LG, de Klerk JM, Zijlstra JM, Fijnheer R, Ludwig I, Kersten MJ, Stoker J, Nievelstein RA. de Jong A, et al. Among authors: kersten mj. J Comput Assist Tomogr. 2016 Mar-Apr;40(2):261-5. doi: 10.1097/RCT.0000000000000338. J Comput Assist Tomogr. 2016. PMID: 26599962
Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, Tonino S, Hutchings M, Spiering M, Liu R, van Tinteren H, Kersten MJ. Hagenbeek A, et al. Among authors: kersten mj. Haematologica. 2019 Apr;104(4):e151-e153. doi: 10.3324/haematol.2018.196899. Epub 2018 Oct 31. Haematologica. 2019. PMID: 30381303 Free PMC article. Clinical Trial. No abstract available.
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group. Lugtenburg PJ, et al. Among authors: kersten mj. Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10. Br J Haematol. 2019. PMID: 31290569 Free article. Clinical Trial.
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK. Awasthi R, et al. Among authors: kersten mj. Blood Adv. 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525. Blood Adv. 2020. PMID: 32045475 Free PMC article. Clinical Trial.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
278 results